Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Research and Markets: Multiple Sclerosis Thought Leader Panel 2012

Research and Markets
Posted on: 12 Oct 12

Research and Markets (http://www.researchandmarkets.com/research/69xx3j/multiple) has announced the addition of the "Multiple Sclerosis Thought Leader Panel #16 2012-05" report to their offering.

BOLT / MedPredict's Multiple Sclerosis Thought Leader Panel #16 summarizes a series of interviews conducted with our Neurology Thought leaders immediately following AAN 2012. The objective of these discussions was to highlight differential clinical advantages that are extrapolatable from the trial data that was presented.

Key areas of focus included:

- Importance of achieving a disease activity-free state

- The future role of ABCR (Interferons and Copaxone) in the era of small molecules and B-cell inhibitors.

- Efficacy and safety of S1P agonists and small molecule immunomodulators

- Natalizumab and JCV risk stratification

- Alemtuzumab

- Daclizumab

- T-cell vaccines

- IL17

Also included in the appendix of this report are compilations of BOLT/MedPredict's Multiple Sclerosis Fantasy Formulary thought exercises from 2Q2010 and 4Q2011. These provide a time lapse picture of Thought Leader excitement for a variety of MS developmental therapeutics.

Key Topics Covered:

Executive Summary

- Report Hightlights

Discussion

- Disease Activity-Free State

-- RRMS

-- Progressive MS

- Interferon and Copaxone (ABCR)

-- CombiRx (Copaxone, Avonex, Combination)

-- Copaxone (glatiramer acetate; Teva)

-- Rebif (Merck-Serono/Pfizer), Avonex (Biogen), Bestaseron (Bayer)

-- PEGylated interferon beta-1a (B11BO17); Biogen

- S1P Receptor Agonists

-- Gilenya; fingolimod (Novartis)

-- siponimod (BAF-312/KRP-203; Kyorin / Novartis)

-- ONO-4641 (Ono / Merck-Serono)

-- Ponesimod ?ACT-128800 (Actelion)

- VLA-4

-- Tysabri; natalizumab (Biogen /Elan)

- Oral Immunimidulators

-- BG-12; fumarate (Biogen-Idec)

-- laquinimod (Teva)

-- teriflunomide (Sanofi-Aventis)

- B-Cell Inhibitors

-- Ocrelizumab (Roche / Biogen-Idec)

-- Ofatumumab (Genmab / GSK)

- Anti-CD-25 (Anti-IL-2)

-- DAC HYP (daclizumab; Biogen)

- CD52

-- Lemdatra / Campath; anti-CD-52; alemtuzumab (Sanofi-Aventis / Bayer-Schering)

- Vaccines / Immune Tolerance

-- Tovaxin (Opexa)

- IL17

-- seculinumab (AIN457; Novartis)

Thought-Leader Discussions

- Interview CNSO2691

- Interview CNSO2692

- Interview CNSO2693

- Interview CNSO2694

- Interview CNSO2695

- Interview CNSO2696

Companies Mentioned

- Actelion

- Bayer

- Bayer-Schering / Sanofi

- Biogen-Idec

- DAC HYP

- Biogen-Idec / Elan

- Biogen-Idec / Genentech / Roche

- GSK / Genmab

- Merck-Serono

- Merck-Serono / Pfizer

- Novartis

- Novartis / Kyorin

- Ono / Merck-Serono

- Opexa

- Roche / Actelion

- Sanofi-Aventis

- Teva / Sanofi-Aventis

- Teva

For more information visit http://www.researchandmarkets.com/research/69xx3j/multiple

Business Wire
http://www.businesswire.com/

Last updated on: 12/10/2012

Advertising